Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

Figures

• 

  FIGURE 1. SPR evaluation of YC-1 and maprotiline binding to sGC immobilized on a sensor chip. (A) SPR sensorgrams of YC-1 binds to sGC with a KD of 2.175 μM. (B) SPR sensorgrams of maprotiline binds to sGC with a KD of 0.307 μM.

• 

  FIGURE 2. Effects of YC-1 (A) and maprotiline (B) on proliferation of HPASMCs under hypoxic conditions in vitro. All values represent means (± SEM) derived from duplicate samples. For statistical significance, #P < 0.05, ##P < 0.01 vs. Nox; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. Hox (0 μM). Each group represents three samples.

• 

  FIGURE 3. Effects of maprotiline on MCT-induced PAH animal model in SD rats. (A) Right ventricular systolic pressure (RVSP); (B) mean pulmonary arterial pressure (mPAP); (C) right ventricular/left ventricle + septum (RV/LV + S); (D) right ventricular/body weight (RV/BW) of different treatment groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. control; #P < 0.05,##P < 0.01 vs. model.

• 

  FIGURE 4. Effects of maprotiline on pulmonary vascular remodeling in MCT-induced PAH. (A) Representative photomicrographs of the pulmonary arterial remodeling indicated by H&E staining (Original magnification 200×, scale bars: 50 μm); (B) percentage of medial wall thickness (WT%); (C) percentage of medial wall area (WA%) of pulmonary arterioles. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. control; #P < 0.05,##P < 0.01,###P < 0.001 vs. model.

• 

  FIGURE 5. Effects of maprotiline on the enzymatic activity of sGC. (A) and on the production of cGMP in lung tissues. (B) All values represent means (± SEM) derived from duplicate samples. ∗P < 0.05 vs. control; #P < 0.05 vs. model.